Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data
Authors' conclusion
Neoadjuvant TKIs may improve the surgical outcomes of patients with advanced DTC. Decision-guided radiological and blood-based surrogate biomarkers, such as TSH, can assist in evaluating treatment response and guide decisions regarding treatment duration and extent of surgical resection.
Study context
- Population
- Patients with advanced or unresectable differentiated thyroid carcinoma (DTC) treated with neoadjuvant TKIs followed by curative-intent surgery, 2023–2025
- Participants
- 9 patients
- Exposure
- Neoadjuvant TKIs followed by curative-intent surgery
- Lenvatinibn = 7
- Dabrafenib/trametinibn = 2
- Outcome
- Radiological response and surgical outcome
Main finding
As reported in the abstract
Median reduction in tumour burden
23.53%
Median duration of TKI therapy
5 months
Observational data: associations, not effects.
Further findings
Elevated TSH during neoadjuvant therapy and treatment response
- Elevated TSH correlated with positive treatment response
- P = 0.028
Original publication
Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data. Clin Endocrinol (Oxf). Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →